Table 2. Association between CYP4Z1 expression and studied immunohistochemical markers.
| Immunohistochemical marker | CYP4Z1-positive n = 187 | CYP4Z1-negative n = 41 | p value |
|---|---|---|---|
| AR | |||
| Positive (n = 125, 54.8%) | 107 (85.4%) | 18 (14.6%) | 0.084 |
| Negative (n = 103, 45.2%) | 80 (77.7%) | 23 (22.3%) | |
| ER | |||
| Positive (n = 129, 56.7%) | 108 (83.7%) | 21 (16.3%) | 0.227 |
| Negative (n = 99, 43.3%) | 79 (79.8%) | 20 (20.2%) | |
| PR | |||
| Positive (n = 105, 46%) | 88 (83.8%) | 17 (16.2%) | 0.317 |
| Negative (n = 123, 54%) | 99 (80.5%) | 24 (19.5%) | |
| EGFR | |||
| Positive (n = 44, 19.3%) | 34 (77.3%) | 10 (22.7%) | 0.239 |
| Negative (n = 184, 80.7%) | 153 (83.2%) | 31 (16.8%) | |
| HER2 | |||
| Positive (n = 164, 71.9%) | 136 (82.9%) | 28 (17.1%) | 0.002 |
| Negative (n = 64, 29.1%) | 51 (79.7%) | 13 (20.3%) | |
| P53 | |||
| Positive (n = 157, 68.8%) | 132 (84.1%) | 25 (15.9%) | 0.02 |
| Negative (n = 71, 31.2%) | 55 (77.5%) | 16 (22.5%) | |
| Ki-67 | |||
| <14% (n = 111, 48.7%) | 93 (79.5%) | 24 (20.5%) | 0.033 |
| >14% (n = 117, 51.3%) | 94 (84.7%) | 17 (15.3%) | |